Hepatocellular Carcinoma | Specialty

TACE Plus Lenvatinib and Pembrolizumab Improves PFS in Intermediate-Stage HCC

September 14th 2024

Lenvatinib, pembrolizumab, and TACE improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma.

FDA Approves Subcutaneous Atezolizumab and Hyaluronidase-tqjs for Use in All Indications of IV Atezolizumab

September 12th 2024

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

Dr El-Khoueiry on Immune Suppression in Advanced HCC After Checkpoint Inhibitors

August 27th 2024

Anthony B. El-Khoueiry, MD, discusses immune suppression in advanced hepatocellular carcinoma post-checkpoint inhibitor therapy.

Atezolizumab/Bevacizumab Represents Potential Therapeutic Option in Child-Pugh B7 HCC

August 12th 2024

Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.

CIRT Plus Durvalumab/Tremelimumab Is Safe in Advanced HCC With Macrovascular Invasion

August 8th 2024

CIRT plus durvalumab and tremelimumab was safe in patients with advanced hepatocellular carcinoma with macrovascular invasion.

EMA Grants Orphan Medicinal Product Designation to Rivoceranib/Camrelizumab in First-Line Unresectable HCC

August 1st 2024

The EMA has granted orphan medicinal product designation to rivoceranib plus camrelizumab in first-line unresectable hepatocellular carcinoma.

Two Leading Experts Detail Hot Topics in GI Cancers to Be Presented at Upcoming ISGIO Meeting

July 31st 2024

Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.

Dr Franses on the Need for Prospective Data in Second-Line HCC and Beyond

July 23rd 2024

Joseph Franses, MD, PhD, discusses the need for more prospective data in the second-line setting and beyond for patients with hepatocellular carcinoma.

Dr Franses on Considerations for Second-Line Treatment of HCC

July 19th 2024

Joseph Franses, MD, PhD, discusses treatment considerations for hepatocellular carcinoma that progresses after first-line therapy.

Complexity in GI Cancer: Questions Are Answered in Gastroesophageal Cancer, Remain in HCC

July 19th 2024

Tanios S. Bekaii-Saab, MD, FACP, details data from the ESOPEC trial in early-stage gastroesophageal cancers, and findings from Checkmate-9DW in HCC.

EMA Validates Application for Nivolumab Plus Ipilimumab in Frontline HCC

July 19th 2024

The type II variation application for frontline nivolumab plus ipilimumab in unresectable/advanced hepatocellular carcinoma was validated by the EMA.

NMPA Accepts sNDA for Toripalimab Plus Bevacizumab as Frontline Therapy in Advanced HCC

July 18th 2024

The National Medical Products Administration accepted for review the supplemental new drug application for toripalimab plus bevacizumab in advanced HCC.

NDA Resubmission Planned for Rivoceranib/Camrelizumab in Unresectable HCC Following FDA CRL

July 9th 2024

Elevar Therapeutics plans to resubmit a new drug application for rivoceranib plus camrelizumab for first-line unresectable hepatocellular carcinoma.

TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers

July 1st 2024

Concordance between TAP score and CPS at matched thresholds indicate their viability for assessing PD-L1 expression in advanced gastric cancers.

Dr Franses on the Feasibility of Co-Inhibiting Angiogenesis and PD-1 Pathways in HCC

June 28th 2024

Joseph Franses, MD, PhD, debates whether targeting angiogenesis and the PD-1/PD-L1 pathway in hepatocellular carcinoma is always a reliable approach.

Dr El-Khoueiry on Regorafenib/Pembrolizumab in Advanced HCC After Prior Anti–PD-1/L1 Therapy

June 24th 2024

Anthony B. El-Khoueiry, MD, on data for regorafenib plus pembrolizumab in pretreated advanced hepatocellular carcinoma.

Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study

June 24th 2024

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Frontline Camrelizumab/Rivoceranib Prolongs OS vs Sorafenib in Unresectable HCC

June 11th 2024

Arndt Vogel, MD, discusses the updated OS analysis of CARES-310, as well as future directions for rivoceranib plus camrelizumab in unresectable HCC.

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

June 2nd 2024

Rivoceranib plus camrelizumab maintained a survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC

May 30th 2024

Frontline rivoceranib plus camrelizumab continued to show a significant improvement in OS vs sorafenib in advanced unresectable hepatocellular carcinoma.